Stockscreener 앱 받기
6.04
3.67%
-0.23
시장 영업 전:
5.99
-0.05
-0.83%
전일 마감가:
$6.27
열려 있는:
$6.3
하루 거래량:
16.19M
Relative Volume:
3.07
시가총액:
$1.69B
수익:
$43.88M
순이익/손실:
$-328.07M
주가수익비율:
-4.3768
EPS:
-1.38
순현금흐름:
$-300.33M
1주 성능:
-17.49%
1개월 성능:
-12.97%
6개월 성능:
-38.24%
1년 성능:
-11.95%
1일 변동 폭
$5.70
$6.37
1주일 범위
$5.70
$7.58
52주 변동 폭
$5.70
$15.74
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RXRX | 6.04 | 1.69B | 43.88M | -328.07M | -300.33M | -1.38 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine - Genetic Engineering & Biotechnology News
Cathie Wood's ARK makes major plays in Recursion, Twist Bioscience stock - Investing.com
RecursionNo News Isn't Good News When It Comes To Vanilla Pipeline (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals’ Strategic Acquisition and Leadership Changes - TipRanks
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery - Wahanariau
Recursion and Exscientia, two leaders in the AI drug - GlobeNewswire
Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline | RXRX Stock News - StockTitan
Recursion Pharmaceuticals stock hits 52-week low at $5.88 - Investing.com India
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year LowHere's What Happened - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $5.88 By Investing.com - Investing.com Canada
Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com Canada
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times
Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan
Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com
Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire
Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance
ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga
Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Pre - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Recursion Pharmace - GuruFocus.com
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - MSN
(RXRX) Technical Pivots with Risk Controls - Stock Traders Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker? - AOL
Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock - Investing.com India
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
6.90%
자본화:
|
볼륨(24시간):